BDBM148218 US8962630, 26

SMILES CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCN(CCO)CC3)nc2n1C1CCCC1

InChI Key InChIKey=NAXBGVSFGBQHDO-UHFFFAOYSA-N

Data  5 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 5 hits for monomerid = 148218   

TargetCyclin-dependent kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM148218(US8962630, 26)
Affinity DataIC50: 1.50E+4nMT: 2°CAssay Description:A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandPNGBDBM148218(US8962630, 26)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-dependent kinase 4(Human)
Novartis

US Patent
LigandPNGBDBM148218(US8962630, 26)
Affinity DataIC50: 26nMpH: 7.5 T: 2°CAssay Description:A 384-well microtiter Lance TR-FRET (time-resolved-fluorescence energy transfer) endpoint assay was used for CDK4/cyclin D1 kinase activity measureme...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-dependent kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM148218(US8962630, 26)
Affinity DataIC50: 1.50E+4nMT: 2°CAssay Description:A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCyclin-dependent kinase 2(Human)
Novartis

US Patent
LigandPNGBDBM148218(US8962630, 26)
Affinity DataIC50: 1.50E+4nMAssay Description:The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384...More data for this Ligand-Target Pair
In DepthDetails
US Patent